Nesvacumab

Source: Wikipedia, the free encyclopedia.
Nesvacumab
Angiopoietin 2
Clinical data
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
IUPHAR/BPS
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6440H9966N1722O2008S38
Molar mass144860.89 g·mol−1

Nesvacumab is an experimental

diabetic macular edema.[3][4]

This drug is being developed by Regeneron Pharmaceuticals.[citation needed]

References

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Nesvacumab, American Medical Association.
  2. PMID 31513439
    .
  3. ^ Clinical trial number NCT02713204 for "Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX)" at ClinicalTrials.gov
  4. ^ Clinical trial number NCT02712008 for "Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema (RUBY)" at ClinicalTrials.gov
Retrieved from "https://en.wikipedia.org/w/index.php?title=Nesvacumab&oldid=1155757286"